PETACH-TIKVA, Israel, November 3, 2016 /PRNewswire/ -- Insuline Medical (TASE: INSL.TA), A medical device research, development and marketing company of injection site treatment and stabilization technologies (ISTS) in order to improve the effectiveness of subcutaneously delivered drugs, announced a significant initial results in a clinical feasibility study with regard to the procedures completed so far. The aim of the study was to test the impact of local treatments at the injection site of long acting insulin (insulin glargine) on insulin levels in the blood and, consequently, the non-invasive influence on blood glucose levels. Basal insulin is typically injected once a day and, unlike mealtime insulin that is injected around meals, basal insulin is intended to keep blood glucose levels stable throughout the day. Treatment with basal insulin is typically the first line of treatment after treatment with oral drugs. Insulin glargine, which is a commonly-used basal insulin drug, resides after injection in a subcutaneous depot from which it is slowly released into the circulation to keep blood glucose levels stable throughout the day. In the above-mentioned study, the effects of local treatments applied to the skin at the basal insulin injection site on glucose and insulin levels in the blood were tested. The treatments applied included cooling, heating, massage, vibration and electrical stimulation. The treatments were tested in relation to their impact on increasing and decreasing the release rates of basal insulin from its subcutaneous drug depot into the circulation, as well as the effects of those rate changes on blood glucose levels. The company has now finalized testing of the local heating and cooling effects on blood glucose levels in 14 type I diabetic subjects that completed three days of testing, including control, "cool" and "heat" tests. During the study subjects injected their daily basal insulin dose in the morning. The experiment started two hours post injection and local interventions were applied to the skin at the injection site for 4 hours, depending on the type of testing conducted that day.